Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling.
Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, imp...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/38800685721149aeb2a7655c6cd80daa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:38800685721149aeb2a7655c6cd80daa |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:38800685721149aeb2a7655c6cd80daa2021-11-18T08:31:17ZLipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling.1932-620310.1371/journal.pone.0089742https://doaj.org/article/38800685721149aeb2a7655c6cd80daa2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24587003/?tool=EBIhttps://doaj.org/toc/1932-6203Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA₄), an anti-inflammatory and pro-resolving lipid mediator that we have recently characterized as an estrogen receptor agonist. LXA₄ treatment significantly reduced endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1β and IL-6, as well as the angiogenic factor VEGF. LXA₄ also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated peritoneal fluid Prostaglandin E₂ (PGE₂) levels. Besides its anti-inflammatory effects, LXA₄ differentially regulated the expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating transforming growth factor (TGF)-β isoform expression within endometriotic lesions and in peritoneal fluid cells. We also report for first time that LXA₄ attenuated aromatase expression, estrogen signaling and estrogen-regulated genes implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA₄ was administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets for the treatment of endometriosis and suggest a pleotropic effect of LXA₄ on disease progression, by attenuating pro-inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as downstream proliferative pathways.Rajesh KumarAnne-Catherine ClercIlaria GoriRonan RussellChiara PellegriniLerisa GovenderJean-Christophe WyssDela GolshayanGeraldine O CannyPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e89742 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Rajesh Kumar Anne-Catherine Clerc Ilaria Gori Ronan Russell Chiara Pellegrini Lerisa Govender Jean-Christophe Wyss Dela Golshayan Geraldine O Canny Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| description |
Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA₄), an anti-inflammatory and pro-resolving lipid mediator that we have recently characterized as an estrogen receptor agonist. LXA₄ treatment significantly reduced endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1β and IL-6, as well as the angiogenic factor VEGF. LXA₄ also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated peritoneal fluid Prostaglandin E₂ (PGE₂) levels. Besides its anti-inflammatory effects, LXA₄ differentially regulated the expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating transforming growth factor (TGF)-β isoform expression within endometriotic lesions and in peritoneal fluid cells. We also report for first time that LXA₄ attenuated aromatase expression, estrogen signaling and estrogen-regulated genes implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA₄ was administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets for the treatment of endometriosis and suggest a pleotropic effect of LXA₄ on disease progression, by attenuating pro-inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as downstream proliferative pathways. |
| format |
article |
| author |
Rajesh Kumar Anne-Catherine Clerc Ilaria Gori Ronan Russell Chiara Pellegrini Lerisa Govender Jean-Christophe Wyss Dela Golshayan Geraldine O Canny |
| author_facet |
Rajesh Kumar Anne-Catherine Clerc Ilaria Gori Ronan Russell Chiara Pellegrini Lerisa Govender Jean-Christophe Wyss Dela Golshayan Geraldine O Canny |
| author_sort |
Rajesh Kumar |
| title |
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| title_short |
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| title_full |
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| title_fullStr |
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| title_full_unstemmed |
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. |
| title_sort |
lipoxin a₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin e₂ production and estrogen signaling. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/38800685721149aeb2a7655c6cd80daa |
| work_keys_str_mv |
AT rajeshkumar lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT annecatherineclerc lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT ilariagori lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT ronanrussell lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT chiarapellegrini lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT lerisagovender lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT jeanchristophewyss lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT delagolshayan lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling AT geraldineocanny lipoxina4preventstheprogressionofdenovoandestablishedendometriosisinamousemodelbyattenuatingprostaglandine2productionandestrogensignaling |
| _version_ |
1718421676396380160 |